A Phase 1 trial testing the safety of an experimental nasal vaccine that may provide enhanced breadth of protection against emerging variants of SARS-CoV-2, the virus that causes COVID-19, is now enrolling healthy adults at three sites in the United States.
NIH/National Institute of Allergy and Infectious Diseases Jul 1 2024 The National Institutes of Health is sponsoring the first-in-human trial of the investigational vaccine, which was designed and tested in pre-clinical studies by scientists from NIH's National Institute of Allergy and Infectious Diseases Laboratory of Infectious Diseases .
Study volunteers will be divided into three cohorts. Those in the first cohort will receive one dose of the investigational vaccine delivered in a nasal spray at the lowest dosage, with enrollees in the next two cohorts receiving progressively higher doses. During seven follow-up visits over about one year, scientists will measure how well the vaccine candidate is tolerated, and if it generates an immune response in the blood and in the nose.
Vaccine Allergy Cell Electron Health And Human Services Immunity Infectious Diseases Laboratory Medical Research Medicine Micrograph Omicron Research Respiratory SARS SARS-Cov-2 Virus
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Study reveals early immune responses to SARS-CoV-2, offering insights for future COVID-19 treatmentsResearchers analyzed early immune responses to SARS-CoV-2 using single-cell multi-omics, revealing key cellular states associated with different infection outcomes.
Read more »
Experimental treatment for metastatic pancreatic cancer shows promise in phase 2 clinical trialClinicians at Georgetown University's Lombardi Comprehensive Cancer Center reported promising preliminary findings based on outcomes in the first six patients with metastatic pancreatic cancer enrolled in a phase 2 clinical trial of the experimental drug BXCL701 in combination with the immunotherapy drug pembrolizumab (Keytruda).
Read more »
Phase III trial shows donidalorsen cuts attack rate in hereditary angioedemaFor patients with hereditary angioedema, donidalorsen reduces the attack rate, according to a study published online May 31 in the New England Journal of Medicine to coincide with the annual congress of the European Academy of Allergy and Clinical Immunology, held from May 31 to June 3 in Valencia, Spain.
Read more »
Proton therapy demonstrates advantages over traditional radiation therapy in Phase III head and neck cancer trialAccording to preliminary data from a multi-institution Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, intensity modulated proton therapy (IMPT) achieved similar clinical outcomes and offered significant patient benefits when compared to traditional intensity modulated radiation therapy (IMRT) as part of...
Read more »
Phase III trial shows lorlatinib highly effective against ALK-positive non–small cell lung cancerA large team of medical researchers and doctors has found via phase III clinical trial that the ALK inhibitor lorlatinib is highly effective for treating non–small cell lung cancer (NSCLC).
Read more »
Leukemia drug passes final trial phase with flying colorsA medication to treat chronic myeloid leukemia (CML) has shown its potential to become the new frontline therapy for people living with the life-threatening blood cancer.
Read more »